Meeting
2011 ASCO Annual Meeting
Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: A U.S. and European international collaborative analysis.
Authors
M. A. Shah
Memorial Sloan-Kettering Cancer Center, New York, NY
M. A. Shah , Y. Y. Janjigian , C. Pauligk , D. Werner , D. P. Kelsen , E. Jaeger , H. Altmannsberger , E. Robinson , L. H. Tang , V. V. Barbashina , S. Al-Batran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal, Gastric, or Small Bowel
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4014)
Abstract #
4014
Poster Bd #
7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinicopathological features of HER2-low expressed advanced gastric cancers.
First Author: Izuma Nakayama
Poster
2020 Gastrointestinal Cancers Symposium
Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts).
First Author: Stacey Stein
Poster
2019 Gastrointestinal Cancers Symposium
A phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2 positive advanced gastric cancer (Ni-HIGH study).
First Author: Daisuke Takahari
First Author: Nora Katzorke